DR KROP: The APHINITY study is a very straightforward trial design that was stimulated by the data from the metastatic setting, in which patients with HER2-positive, early-stage disease are going to be randomized to essentially any standard adjuvant regimen, either a TCH or any anthracycline/taxane regimen — there’s a lot of flexibility because it’s a global trial — either with placebo or pertuzumab when trastuzumab is given. So the pertuzumab or placebo is started whenever you’re going to give trastuzumab. So it's a very flexible study. It’s about 3,800 patients.
DR LOVE: And what’s the eligibility in terms of risk?
DR KROP: So it’s open to node-positive or node-negative with some high-risk feature, either greater than 1 centimeter, hormone receptor-negative or high grade. They’re limiting those lower-risk node-negative patients to 10 percent of the overall population. But it’s certainly going to be applicable to the majority of our patients with early-stage HER2-positive disease.